GGrantIndex
← Leaderboards

Paul E Monahan

University Of North Carolina Chapel Hill

$4,569,284
Attributed
$4,569,284
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $568.2K · FY200517
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17

Funding mix

By agency

CDC$2,661,305 · 2
NIH$1,907,979 · 4

By mechanism

U01$2,661,305 · 1
P01$1,491,451 · 2
K08$416,526 · 1
P30$2 · 1
U27$0 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of North Carolina Chapel Hill

Same institution · by research overlap

Others in their field

Top investigators on “Gene Therapy

Research focus

Gene TherapyGene ExpressionNeutralizing AntibodyHemophilia BVirusComplementResponseInstitutionVectorSafetyGenesAdeno-Associated Viral VectorDoseGene DeliveryHemophilia AEvaluationViral VectorChondrocytesAdjuvantChronicCodon NucleotidesChildhoodDependovirusDeveloped Countries

Grant awards (25)

INTRAARTICULAR AAV TO CIRCUMVENT SYSTEMIC NEUTRALIZATION$149,913
P01 · FY2017 · HL · contact PI
INTRAARTICULAR AAV TO CIRCUMVENT SYSTEMIC NEUTRALIZATION$149,911
P01 · FY2017 · HL · contact PI
INTRAARTICULAR AAV TO CIRCUMVENT SYSTEMIC NEUTRALIZATION$152,001
P01 · FY2016 · HL · contact PI
INTRAARTICULAR AAV TO CIRCUMVENT SYSTEMIC NEUTRALIZATION$151,999
P01 · FY2016 · HL · contact PI
INTRAARTICULAR AAV TO CIRCUMVENT SYSTEMIC NEUTRALIZATION$149,529
P01 · FY2015 · HL · contact PI
INTRAARTICULAR AAV TO CIRCUMVENT SYSTEMIC NEUTRALIZATION$149,528
P01 · FY2015 · HL · contact PI
INTRAARTICULAR AAV TO CIRCUMVENT SYSTEMIC NEUTRALIZATION$150,087
P01 · FY2014 · HL · contact PI
INTRAARTICULAR AAV TO CIRCUMVENT SYSTEMIC NEUTRALIZATION$150,083
P01 · FY2014 · HL · contact PI
INTRAARTICULAR AAV TO CIRCUMVENT SYSTEMIC NEUTRALIZATION$288,400
P01 · FY2013 · HL · contact PI
Prevention of the Complications of Bleeding Disorder Through HTCs$456,667
U01 · FY2010 · DD · contact PI
Prevention of the Complications of Bleeding Disorder Through HTCs$534,113
U01 · FY2009 · DD · contact PI
Gene Transfer Clinical Core Unit$2
P30 · FY2009 · DK · contact PI
Prevention of the Complications of Bleeding Disorder Through HTCs$534,113
U01 · FY2008 · DD · contact PI
Prevention of the Complications of Bleeding Disorder Through HTCs$568,206
U01 · FY2007 · DD · contact PI
Prevention of the Complications of Bleeding Disorder Through HTCs$568,206
U01 · FY2006 · DD · contact PI
PREVENTION OF THE COMPLICATIONS OF HEMOPHILIA THROUGH HTCS$0
U27 · FY2005 · DD
PREVENTION OF THE COMPLICATIONS OF HEMOPHILIA THROUGH HTCS$0
U27 · FY2004 · DD
AAV DIRECTED MUSCLE GENE THERAPY FOR HEMOPHILIA B$114,077
K08 · FY2003 · HL
PREVENTION OF THE COMPLICATIONS OF HEMOPHILIA THROUGH HTCS$0
U27 · FY2003 · DD
AAV DIRECTED MUSCLE GENE THERAPY FOR HEMOPHILIA B$114,077
K08 · FY2002 · HL
PREVENTION OF THE COMPLICATIONS OF HEMOPHILIA THROUGH HTCS$0
U27 · FY2002 · DD
AAV DIRECTED MUSCLE GENE THERAPY FOR HEMOPHILIA B$114,077
K08 · FY2001 · HL
PREVENTION OF THE COMPLICATIONS OF HEMOPHILIA THROUGH HTCS$0
U27 · FY2001 · DD
AAV DIRECTED MUSCLE GENE THERAPY FOR HEMOPHILIA B$74,295
K08 · FY2000 · HL
PREVENTION OF THE COMPLICATIONS OF HEMOPHILIA THROUGH HTCS$0
U27 · FY2000 · DD